Company / Operating Income
Sonoma Pharmaceuticals, Inc. Operating Income History
FY2017-FY2026 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$3.7M
FY2026
5-year range
-$5.9M / -$3.4M
FY2022-FY2026
Trend
+21.1%
vs FY2025
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 10 years, ranging from -$15M in FY2017 to -$3M in FY2022.
Based on SEC 10-K filings.
-$4M in FY2026.
Improved from -$5M to -$4M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2026, operating income increased 21.1% year-over-year.
- Peak operating income was recorded in FY2022.
- Lowest operating income in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2026 | -$3.7M | +21.1% |
| FY2025 | -$4.7M | -2.9% |
| FY2024 | -$4.6M | +22.4% |
| FY2023 | -$5.9M | -70.7% |
| FY2022 | -$3.4M | +53.3% |
| FY2021 | -$7.4M | +34.4% |
| FY2020 | -$11.3M | +20.7% |
| FY2019 | -$14.2M | -9.4% |
| FY2018 | -$13.0M | +11.8% |
| FY2017 | -$14.7M | -121.0% |
As of FY2026 · SEC 10-K · Updated Jun 28, 2026